Quarterly report pursuant to Section 13 or 15(d)

Subsequent Event

v3.19.2
Subsequent Event
6 Months Ended
Jun. 30, 2019
Subsequent Events [Abstract]  
Subsequent Event Subsequent EventOn July 23, 2019, we acquired privately-held Ab Initio Biotherapeutics, Inc., an antigen-discovery company located in South San Francisco, California. We paid approximately $12.0 million for the acquisition.